EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identifying Hemolytic Disease of the Fetus and Newborn within a Large Integrated Health Care System

Fagen Xie iD, Michael J Fassett, Jiaxiao M Shi, Vicki Y Chiu, Theresa M Im, Sunhea Kim, Nana A Mensah, Nehaa Khadka, Daniella Park, Carol Mao, Matthew Molaei, Iris Lin und 1 weitere

American Journal of Perinatology · 01.05.2025 · 42 (07) · 924-932

DOI: 10.1055/a-2444-2314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2025. Verfasst von Fagen Xie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. Hauptthemen laut MEDLINE: Erythroblastosis, Fetal, Delivery of Health Care, Integrated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to identify hemolytic disease of the fetus and newborn (HDFN) pregnancies using electronic health records (EHRs) from a large integrated health care system. A retrospective cohort study was performed among pregnant patients receiving obstetrical care at Kaiser Permanente Southern California health care system between January 1, 2008, and June 30, 2022. Using structured (diagnostic/procedural codes, medication, and laboratory records) and unstructured (clinical notes analyzed via natural language processing) data abstracted from EHRs, we extracted HDFN-specific “indicators” (maternal positive antibody test and abnormal antibody titer, maternal/infant HDFN diagnosis and blood transfusion, hydrops fetalis, infant intravenous immunoglobulin [IVIG] treatment, jaundice/phototherapy, and first administrated Rho[D] Immune Globulin) to identify potential HDFN pregnancies. Chart reviews and adjudication were then performed on select combinations of indicators for case ascertainment. HDFN due to ABO alloimmunization alone was excluded. The HDFN frequency and proportion of each combination were fully analyzed. Among the 464,711 eligible pregnancies, a total of 136 pregnancies were confirmed as HDFN pregnancies. The percentage of the HDFN-specific indicators ranged from 0.02% (infant IVIG treatment) to 34.53% (infant jaundice/phototherapy) among the eligible pregnancies, and 32.35% (infant IVIG treatment) to 100% (maternal positive antibody test) among the 136 confirmed HDFN pregnancies. Four combination groups of four indicators, four combination groups of five indicators, and the unique combination of six indicators showed 100% of HDFN pregnancies, while 80.88% of confirmed HDFN pregnancies had the indicator combination of maternal positive antibody test, maternal/infant HDFN diagnosis, and infant jaundice/phototherapy. We successfully identified HDFN pregnancies by leveraging a combination of medical indicators extracted from structured and unstructured data that may be used in future pharmacoepidemiologic studies. Traditional indicators (positive antibody test results, high titers, and clinical diagnosis codes) alone did not accurately identify HDFN pregnancies, highlighting an unmet need for improved practices in HDFN coding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erythroblastosis, FetalDelivery of Health Care, IntegratedHumansFemalePregnancyRetrospective StudiesInfant, NewbornAdultElectronic Health RecordsCaliforniaImmunoglobulins, IntravenousPhototherapy

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
  • Department of Obstetrics and Gynecology, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California.
  • Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
  • Janssen Global Services LLC, a Johnson & Johnson company, Horsham, Pennsylvania.
  • Janssen Scientific Affairs LLC, a Johnson & Johnson company, Horsham, Pennsylvania.
  • Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.

ORCID-Profile: Fagen Xie, Darios Getahun

Zitieren

APA

Xie, F., Fassett, M. J., Shi, J. M., Chiu, V. Y., Im, T. M., Kim, S., Mensah, N. A., Khadka, N., Park, D., Mao, C., Molaei, M., Lin, I., & Getahun, D. (2025). Identifying Hemolytic Disease of the Fetus and Newborn within a Large Integrated Health Care System. American Journal of Perinatology, 42(07), 924-932. https://doi.org/10.1055/a-2444-2314

Vancouver

Xie F, Fassett MJ, Shi JM, Chiu VY, Im TM, Kim S, et al. Identifying Hemolytic Disease of the Fetus and Newborn within a Large Integrated Health Care System. American Journal of Perinatology. 2025;42(07):924-932. doi:10.1055/a-2444-2314

BibTeX
@article{Xie2025,
  author = {Xie, Fagen and Fassett, Michael J and Shi, Jiaxiao M and Chiu, Vicki Y and Im, Theresa M and Kim, Sunhea and Mensah, Nana A and Khadka, Nehaa and Park, Daniella and Mao, Carol and Molaei, Matthew and Lin, Iris and Getahun, Darios},
  title = {Identifying Hemolytic Disease of the Fetus and Newborn within a Large Integrated Health Care System},
  journal = {American Journal of Perinatology},
  year = {2025},
  volume = {42},
  number = {07},
  pages = {924--932},
  doi = {10.1055/a-2444-2314}
}
Kostenlos starten →